VICTORIA: Vericiguat Response and Outcomes by Index Heart Failure Event

November 13-17, 2020; Virtual Conference
Risk of CV death or hospitalization for HF was highest in patients with hospitalization for HF within 3 months prior to study.
Format: Microsoft PowerPoint (.ppt)
File Size: 331 KB
Released: November 18, 2020

Acknowledgements

Provided by Clinical Care Options

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck

Related Content

Expert commentary on updates to the 2022 AHA/ACC/HFSA heart failure guidelines, from Clinical Care Options (CCO)

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: May 10, 2022 Expired: May 9, 2023

Clinical Care Options (CCO): Expert commentary covering new data in HFpEF diagnosis and treatment from ACC 2022 Annual Scientific Sessions

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: April 26, 2022 Expired: April 25, 2023

Clinical Care Options (CCO): Expert commentary covering new data in HFrEF management from ACC 2022, including SODIUM-HF, PROMPT-HF, DIAMOND, and EMPULSE

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: April 20, 2022 Expired: April 19, 2023

From ACC 2022, exploratory analysis of renal outcomes with sacubitril/valsartan vs valsartan in HFpEF with and without diabetes in PARAGON-HF trial as reported by Clinical Care Options (CCO)

Released: April 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings